Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Once Daily Mexiletine PR During 26 Weeks of Treatment in Patients With Myotonic Dystrophy Type 1 and Type 2 (Phase 3)
NCT06523400 is registered in ClinicalTrials.gov with Lupin Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Once Daily Mexiletine PR During 26 Weeks of Treatment in Patients With Myotonic Dystrophy Type 1 and Type 2 (Phase 3)
- Lead sponsor
- Lupin Ltd.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- February 13, 2025
- Completion date
- June 30, 2027
- Enrollment
- 176 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.